Clinical Trials Logo

Clinical Trial Summary

This pilot study will evaluate the safety and efficacy of once daily T2000 when used to treat patients with Myoclonus Dystonia over a 12 week period.


Clinical Trial Description

Myoclonus Dystonia (M-D) is a rare, inherited movement disorder in which patients experience myoclonus - sudden, brief, jerky involuntary motions, often in association with dystonia - involuntary sustained contractions causing twisting or abnormal posture. While most M-D patients respond significantly to alcohol, there are no approved medications for M-D. A variety of medications are currently used to treat M-D, but these treatments work in a small proportion of patients and provide only partial improvement in symptoms; their use is also limited by side-effects in many patients.

T2000 is a medication currently under development for the treatment of movement disorders, including essential tremor (ET). Although T2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. In previous studies, T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET had major improvements in tremor. As would be expected for medications in this class, T2000 can cause sedation at high blood levels, such as may be seen when large doses are given to older individuals. In younger patients, T2000 caused only minimal side effects even when administered at high doses and for periods of several weeks to several months.

The current study will evaluate the safety and efficacy of T2000 in patients with M-D. Patients will receive doses of T2000 beginning at 200 mg a day and increasing every other week by an additional 200 mg a day up to a maximal dose of 1000 mg a day. The total duration of treatment will be 12 weeks. Patient's symptoms of myoclonus and dystonia, as well as overall neurological examination, will be monitored throughout the study. The response to T2000 will be determined by comparing the severity of myoclonus and dystonia while patients are receiving T2000 compared to the symptoms observed without active medication. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00506012
Study type Interventional
Source Taro Pharmaceuticals USA
Contact
Status Terminated
Phase Phase 2
Start date August 2007
Completion date October 2011

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02518789 - Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus Phase 4
Completed NCT04235452 - Electrophysiological Characteristics and Anatomical Differentiation of Epileptic and Non-epileptic Myoclonus.
Completed NCT00001667 - Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases N/A
Not yet recruiting NCT05754762 - Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate Injection N/A
Completed NCT00244361 - Effectiveness of Rituximab in Pediatric OMS Patients. Phase 1/Phase 2
Recruiting NCT05317390 - Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia N/A
Completed NCT00001663 - Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation Phase 1
Recruiting NCT00029965 - Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders